Immunohistochemical assay revealed that the tumor tissues in the oeDT plus pembrolizumab group showed significantly less Ki-67 expression level than the shDT plus pembrolizumab group (Table S7, Figure S5). The gene discussed is MKI67; the disease is neoplasm.